The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Generic options provide limited savings for high-priced cancer drugs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Generic drug options did not significantly reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs paper published May 10.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Friends publishes three white papers ahead of annual meeting

The Friends of Cancer Research annual meeting, to be held Nov. 4 in Washington, DC, will focus on three questions facing the field of oncology clinical trial design: How do clinical researchers create seamless trial designs for drug development in rare cancers?What are the considerations for clinical trial design testing combination drug development? How can clinical researchers address variability in standards of care in multi-regional clinical trials?
By Sara Willa Ernst
ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account